Literature DB >> 22156800

Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model.

Leslie C Costello1, Renty B Franklin, Jing Zou, Pei Feng, Robert Bok, Mark G Swanson, John Kurhanewicz.   

Abstract

Prostate cancer is the second leading cause of cancer deaths among men. The availability of animal models that represent the events and factors that exist in the natural history and biology of human prostate cancer is essential in dealing with prostate cancer. In recent decades and presently, emphasis has been directed at the development and employment of prostate cancer induced in transgenic mice. However, the important consistent hallmark characteristic and event of decrease in zinc and citrate and downregulation of ZIP1 zinc transporter in prostate malignancy has not been studied or identified in any animal model. We investigated the status of these parameters in TRAMP tumors as compared with human prostate cancer. The results show that citrate levels are markedly decreased in the developing and advancing stages of malignancy in TRAMP. Zinc levels are also decreased and ZIP1 transporter is lost in TRAMP tumors. In vitro studies show that zinc treatment of TRAMP C2 cells exhibits cytotoxic effects. Collectively, these results mimic the ZIP1, zinc, and citrate status and relationship that exist in human prostate cancer. This is the first report that establishes the existence of the human prostate zinc/citrate hallmark characteristic and relationship in an animal model. It now appears that the TRAMP model will be suitable for studies relating to the implications and role of zinc- and citrate-related metabolism in the development and progression of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156800      PMCID: PMC3335941          DOI: 10.4161/cbt.12.12.18367

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  23 in total

1.  Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone.

Authors:  L C Costello; Y Liu; J Zou; R B Franklin
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

Review 2.  The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy.

Authors:  L C Costello; R B Franklin
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

3.  HISTOCHEMICAL DEMONSTRATION OF ZINC IN THE DORSOLATERAL PROSTATE OF THE RAT: STUDIES WITH OXINE AND DITHIZONE.

Authors:  S S STERNBERG; A CRONIN; F S PHILIPS
Journal:  Am J Pathol       Date:  1965-08       Impact factor: 4.307

Review 4.  The genetic/metabolic transformation concept of carcinogenesis.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

5.  Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands.

Authors:  Leslie A Johnson; Mazhar A Kanak; Andre' Kajdacsy-Balla; Joseph P Pestaner; Omar Bagasra
Journal:  Methods       Date:  2010-08-10       Impact factor: 3.608

6.  Citric acid in human prostatic secretion and metastasizing cancer of prostate gland.

Authors:  H MARBERGER; E MARBERGER; T MANN; C LUTWAK-MANN
Journal:  Br Med J       Date:  1962-03-24

7.  Protein kinase C alpha, epsilon and AP-1 mediate prolactin regulation of mitochondrial aspartate aminotransferase expression in the rat lateral prostate.

Authors:  R B Franklin; J Zou; J Ma; L C Costello
Journal:  Mol Cell Endocrinol       Date:  2000-12-22       Impact factor: 4.102

8.  Zinc and magnesium in human prostate gland: normal, hyperplastic, and neoplastic.

Authors:  F Györkey; K W Min; J A Huff; P Györkey
Journal:  Cancer Res       Date:  1967-08       Impact factor: 12.701

9.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

Authors:  B A Foster; J R Gingrich; E D Kwon; C Madias; N M Greenberg
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

10.  Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells.

Authors:  R B Franklin; J Ma; J Zou; Z Guan; B I Kukoyi; P Feng; L C Costello
Journal:  J Inorg Biochem       Date:  2003-08-01       Impact factor: 4.155

View more
  30 in total

1.  Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach.

Authors:  Leslie C Costello; Renty B Franklin; Jing Zou; Michael J Naslund
Journal:  Chemotherapy (Los Angel)       Date:  2015-06

2.  Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.

Authors:  Lang Wu; Kari G Chaffee; Alexander S Parker; Hugues Sicotte; Gloria M Petersen
Journal:  Tumour Biol       Date:  2015-04-23

3.  Reassessment of the Transport Mechanism of the Human Zinc Transporter SLC39A2.

Authors:  Marie C Franz; Jonai Pujol-Giménez; Nicolas Montalbetti; Miguel Fernandez-Tenorio; Timothy R DeGrado; Ernst Niggli; Michael F Romero; Matthias A Hediger
Journal:  Biochemistry       Date:  2018-06-07       Impact factor: 3.162

4.  Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.

Authors:  Hsin-Yu Chen; Peder E Z Larson; Robert A Bok; Cornelius von Morze; Renuka Sriram; Romelyn Delos Santos; Justin Delos Santos; Jeremy W Gordon; Naeim Bahrami; Marcus Ferrone; John Kurhanewicz; Daniel B Vigneron
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

Review 5.  A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Arch Biochem Biophys       Date:  2016-04-27       Impact factor: 4.013

Review 6.  Metabolic targets for potential prostate cancer therapeutics.

Authors:  Jeffrey Twum-Ampofo; De-Xue Fu; Antonino Passaniti; Arif Hussain; M Minhaj Siddiqui
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

7.  Zinc as an Imaging Biomarker of Prostate Cancer.

Authors:  Su-Tang Lo; André F Martins; Veronica Clavijo Jordan; A Dean Sherry
Journal:  Isr J Chem       Date:  2017-07-31       Impact factor: 3.333

Review 8.  Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Expert Opin Ther Targets       Date:  2016-12-05       Impact factor: 6.902

Review 9.  Citrate chemistry and biology for biomaterials design.

Authors:  Chuying Ma; Ethan Gerhard; Di Lu; Jian Yang
Journal:  Biomaterials       Date:  2018-05-04       Impact factor: 12.479

10.  Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate.

Authors:  M Veronica Clavijo Jordan; Su-Tang Lo; Shiuhwei Chen; Christian Preihs; Sara Chirayil; Shanrong Zhang; Payal Kapur; Wen-Hong Li; Luis M De Leon-Rodriguez; Angelo J M Lubag; Neil M Rofsky; A Dean Sherry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.